Bicocca Open Archive

Logo unimib boa
BIDOLI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.572
AS - Asia 4.215
EU - Europa 3.501
SA - Sud America 731
AF - Africa 63
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 17.092
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.404
SG - Singapore 1.526
HK - Hong Kong 1.052
CN - Cina 991
RU - Federazione Russa 812
IE - Irlanda 609
BR - Brasile 596
IT - Italia 558
DE - Germania 470
SE - Svezia 460
VN - Vietnam 230
GB - Regno Unito 161
CA - Canada 124
UA - Ucraina 112
IN - India 94
AT - Austria 68
FI - Finlandia 60
AR - Argentina 58
ID - Indonesia 58
TR - Turchia 48
JP - Giappone 43
FR - Francia 42
BD - Bangladesh 39
DK - Danimarca 38
MX - Messico 30
KR - Corea 25
IQ - Iraq 23
ZA - Sudafrica 23
NL - Olanda 22
EC - Ecuador 20
PL - Polonia 20
BE - Belgio 19
ES - Italia 15
SA - Arabia Saudita 15
CO - Colombia 13
VE - Venezuela 10
PE - Perù 9
PY - Paraguay 9
UY - Uruguay 9
UZ - Uzbekistan 9
IR - Iran 8
PK - Pakistan 8
AE - Emirati Arabi Uniti 6
AU - Australia 6
CL - Cile 6
EG - Egitto 5
JM - Giamaica 5
JO - Giordania 5
KE - Kenya 5
MU - Mauritius 5
NP - Nepal 5
RO - Romania 5
AM - Armenia 4
BG - Bulgaria 4
DZ - Algeria 4
MA - Marocco 4
TN - Tunisia 4
TW - Taiwan 4
AL - Albania 3
DO - Repubblica Dominicana 3
IL - Israele 3
KZ - Kazakistan 3
LT - Lituania 3
NG - Nigeria 3
PS - Palestinian Territory 3
SN - Senegal 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
EU - Europa 2
GR - Grecia 2
IS - Islanda 2
LB - Libano 2
MT - Malta 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
CH - Svizzera 1
CY - Cipro 1
ET - Etiopia 1
GA - Gabon 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
ML - Mali 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
Totale 17.086
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.331
Hong Kong 1.037
Singapore 943
Fairfield 850
Ashburn 795
Dublin 601
Woodbridge 481
Wilmington 435
Seattle 389
Chandler 372
Houston 323
Cambridge 320
Frankfurt am Main 281
New York 274
Princeton 248
Beijing 212
Jacksonville 166
Santa Clara 145
Shanghai 129
Altamura 122
Lawrence 118
Los Angeles 118
Milan 110
Dallas 92
Chicago 87
The Dalles 80
Moscow 77
San Diego 73
Dearborn 63
Ho Chi Minh City 62
Toronto 52
São Paulo 50
Jakarta 48
Vienna 48
Buffalo 45
Andover 44
Hanoi 42
London 39
Guangzhou 38
Boardman 34
Helsinki 34
Hefei 32
Nanjing 32
Salt Lake City 30
Munich 29
Hangzhou 28
Rio de Janeiro 27
Nuremberg 26
Turin 26
Ottawa 25
Tokyo 25
Pune 24
Washington 24
Falls Church 23
Dong Ket 22
Council Bluffs 20
Rome 20
Brussels 18
Norwalk 18
Seoul 16
Jinan 15
Phoenix 15
Tianjin 15
Columbus 14
Tampa 14
Brasília 13
Hebei 13
Redmond 13
San Francisco 13
Zhengzhou 13
Atlanta 12
Boston 12
Elk Grove Village 12
Lachine 12
Torre Del Greco 12
Changsha 11
Porto Alegre 11
Warsaw 11
Belo Horizonte 10
Brooklyn 10
Haiphong 10
Tappahannock 10
Chennai 9
Da Nang 9
Guayaquil 9
Johannesburg 9
Amsterdam 8
Baghdad 8
Dhaka 8
Edmonton 8
Mumbai 8
Nanchang 8
Perugia 8
Poplar 8
Stockholm 8
Tashkent 8
Biên Hòa 7
Düsseldorf 7
Fremont 7
Genoa 7
Totale 11.688
Salva come PNG Salva come JPEG
Nome #
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 382
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 344
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 324
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 312
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 302
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 302
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 292
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 286
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 269
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 267
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 260
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 257
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 241
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 239
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 239
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 224
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 215
When progressive dysphagia could be related to an “old friend” – a case report 204
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 204
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 199
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 196
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 193
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 190
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 180
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 178
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 172
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 171
Novel cytotoxic chemotherapies in small cell lung carcinoma 171
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 166
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 163
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 157
Focus on nivolumab in NSCLC 155
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 155
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 154
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 152
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 152
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 151
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 148
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 146
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 145
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 141
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 140
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 140
Drugs ten years later: epirubicin 137
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer 136
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 135
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 134
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 132
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 131
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 130
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 128
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 128
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 126
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 126
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 123
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 123
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 119
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 118
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 117
Pilot study with adriamycin and ifosfamide in small cell lung cancer 117
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 115
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 114
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 114
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 113
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 113
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 113
A new race against lung cancer 111
Oxaliplatin doublets in non-small cell lung cancer: A literature review 111
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 111
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 110
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 109
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 109
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 107
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 107
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 107
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 106
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 106
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 105
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 105
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 105
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 104
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial 104
Targeted therapies and immunotherapy in non-small-cell lung cancer 103
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 102
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 101
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 100
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 100
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 99
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients 98
Isolated cardiac metastasis from squamous cell esophageal cancer 97
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial 97
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 97
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 96
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 95
Esophageal carcinoma: radiochemotherapy 94
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 94
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 94
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 93
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC) 93
Combined radiation and chemotherapy in esophageal cancer 92
Totale 15.382
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.831
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.831
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.610 0 0 0 0 0 185 293 324 219 220 179 190
2021/20221.233 107 156 159 71 40 86 79 62 67 53 96 257
2022/20231.894 273 635 127 134 83 303 33 99 131 21 30 25
2023/20241.867 32 36 59 59 272 498 377 101 205 14 17 197
2024/20253.752 219 500 198 171 301 132 213 80 463 555 277 643
2025/20263.416 783 521 464 642 908 98 0 0 0 0 0 0
Totale 17.700